SLSSELLAS Life Sciences GroupSLS info
$1.22info-3.17%24h
Global rank24881
Market cap$53.05M
Change 7d-6.87%
YTD Performance11.93%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    SELLAS Life Sciences Group (SLS) Stock Overview

    SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

    SLS Stock Information

    Symbol
    SLS
    Address
    Times Square TowerNew York, NY 10036United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.sellaslifesciences.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    646 200 5278

    SELLAS Life Sciences Group (SLS) Price Chart

    -
    Value:-

    SELLAS Life Sciences Group Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.22
    N/A
    Market Cap
    $53.05M
    N/A
    Shares Outstanding
    43.49M
    N/A
    Employees
    17.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org